## Cais Rhyddid Gwybodaeth / Freedom of Information request Ein Cyf / Our Ref: 23-C-024

## You asked:

I am researching the incidence and treatment of Urothelial and Colorectal Cancer. I would greatly appreciate if you could answer the following two questions.

Please note the information below is for the three month period December 2022 to February 2023;

Q1. How many urothelial cancer patients have been treated in the past 3 months with the following agents:

- Avelumab - < 5*
- Atezolizumab <5*
- Carboplatin with Gemcitabine - 8
- Carboplatin single or in any other combination - 0
- Cisplatin with Gemcitabine <5*
- Cisplatin single or in any other combination - 0
- Nivolumab - 0
- Pembrolizumab - 0
- Any other regimen including Paclitaxel - 0
- Any other chemotherapy regimen - 0
- Other active systemic anti-cancer therapy- 0
- Palliative care only - this is not held centrally**


## Q2. How many colorectal cancer [CRC] patients have been treated in the past 3 months with the following agents:

- Aflibercept - 0
- Bevacizumab-0
- Capecitabine - 19
- CAPIRI <5*
- CAPOX (XELOX) - 0
- Cetuximab in combination with FOLFIRI <5*
- Cetuximab in combination with FOLFOX - 0

- Cetuximab not in combination with FOLFIRI or FOLFOX < 5*
- Irinotecan only <5*
- FOLFIRI - 18
- FOLFOX - 12
- Fluorouracil (5FU) only - 0
- Oxaliplatin only - 0
- Panitumumab in combination with FOLFIRI <5*
- Panitumumab in combination with FOLFOX - 5
- Panitumumab not in combination with FOLFIRI or FOLFOX <5*
- Pembrolizumab-0
- Nivolumab-0
- Raltitrexed - 0
- Ramucirumab-0
- Regorafenib <5*
- Sorafenib-0
- Other active systemic anti-cancer therapy - 20
- Palliative care only - this is not held centrally**


#### Abstract

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test. ** To obtain this information would involve a manual trawl and search of patient records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.


